SCHEMBL11027562

SCHEMBL11027562

Cc1ccc(N2CCOC2=O)cc1C1CC(C)(C)c2cc(C(=O)O)ccc2N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKAG1 P54619 3/20 0.38
▸ PRKAA1 Q13131 3/20 0.38
▸ PRKAB1 Q9Y478 3/20 0.38
▸ PRKAB2 O43741 1/20 0.38
▸ PRKAA2 P54646 1/20 0.38
▸ PRKAG3 Q9UGI9 1/20 0.38
▸ PRKAG2 Q9UGJ0 1/20 0.38
▸ ELOVL6 Q9H5J4 1/20 0.37
▸ SSTR5 P35346 4/20 0.35
▸ CMA1 P23946 1/20 0.34
▸ IDH1 O75874 2/20 0.33
▸ BCL2 P10415 1/20 0.33
▸ CCNA2 P20248 3/20 0.33
▸ CDK2 P24941 3/20 0.33
▸ CCNA1 P78396 3/20 0.33
▸ KDM1A O60341 2/20 0.33
▸ MAOA P21397 2/20 0.33
▸ MAOB P27338 2/20 0.33
▸ RCOR1 Q9UKL0 2/20 0.33
▸ CCNB2 O95067 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11031494 0.92 ELOVL6 (0.38) PRKAG1PRKAA1PRKAB1ELOVL6IDH1
SCHEMBL11026667 0.90 PRKAG1 (0.42) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL11025472 0.88 ELOVL6 (0.37) ELOVL6CCNA2CDK2CCNA1KDM1A
SCHEMBL11940890 0.85 SCN9A (0.37) ELOVL6
SCHEMBL11025981 0.84 KMO (0.43) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL11026176 0.82 ELOVL6 (0.38) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL11024397 0.80 PRKAG1 (0.45) PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2
SCHEMBL11029510 0.79 SCN9A (0.37) PRKAG1PRKAA1PRKAB1ELOVL6KDM1A
SCHEMBL11940889 0.77 IP6K1 (0.38) ELOVL6CCNA2CDK2CCNA1KDM1A
SCHEMBL11028020 0.76 PRKAG1 (0.40) PRKAG1PRKAA1PRKAB1MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809369-B2 Tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2014-08-19 — — US disclosed
EP-2668165-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2013-12-04 — — EP disclosed
WO-2012101068-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-08-02 — — WO disclosed
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES RAB1A, RABL3, RAB7A PRKAG1 2822/4885PRKAA1 2934/4885PRKAB1 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback